Investigational daily pill lowered bad cholesterol as much as injectables

A new oral PCSK9 inhibitor, enlicitide, demonstrated significant efficacy in a Phase 3 trial, reducing LDL cholesterol by up to 60% and showing comparable results to existing injectable PCSK9 inhibitors. Presented at the American Heart Association’s Scientific Sessions 2025, this daily pill offers a more convenient alternative for high-risk patients whose cholesterol remains elevated despite statin therapy. While preliminary, these findings suggest enlicitide could become a major new entrant in the cardiovascular drug market, potentially improving patient adherence and expanding the reach of PCSK9 inhibition, though a longer outcomes study is ongoing to confirm cardiovascular event reduction.

Analysis

A new oral PCSK9 inhibitor, enlicitide, demonstrated significant efficacy in the Phase 3 CORALreef Lipids trial, reducing LDL cholesterol by up to 60% and maintaining these reductions for 52 weeks. This daily medication achieved comparable LDL, non-HDL, and ApoB reductions to existing injectable PCSK9 inhibitors like alirocumab and evolocumab, and numerically superior results to inclisiran. The study involved 2,912 high-risk adults whose LDL levels remained elevated despite standard lipid-lowering therapies.

The oral formulation of enlicitide presents a substantial convenience advantage over current injectable PCSK9 inhibitors, potentially enhancing patient adherence and expanding market access for this class of drugs. This could address the unmet need for patients struggling to reach guideline-recommended cholesterol targets, offering a powerful new option for cardiovascular risk reduction. The preliminary findings, presented at AHA Scientific Sessions 2025, suggest a strong potential for market disruption.

Despite the promising results, these findings are preliminary, derived from a research abstract, and are not yet peer-reviewed. A longer, ongoing CORALreef outcomes trial is crucial to definitively determine enlicitide's ability to reduce major cardiovascular events. Investors should monitor the progress of this outcomes study and the eventual peer-reviewed publication for full validation.

Key Decisions for Investors

• Monitor the progress of enlicitide's ongoing CORALreef outcomes trial and its eventual peer-reviewed publication for definitive cardiovascular event reduction data.
• Evaluate potential market entrants in the oral PCSK9 inhibitor space, as enlicitide's convenience could significantly disrupt the current injectable PCSK9 market and expand patient access.
• Assess the competitive landscape and potential impact on companies currently marketing injectable PCSK9 inhibitors, given enlicitide's comparable efficacy and superior convenience profile.